Evaluation of Safety of Treatment With Anti–Epidermal Growth Factor Receptor Antibody Drug Conjugate MRG003 in Patients With Advanced Solid Tumors-Reference-Cited by-全球学者库

Evaluation of Safety of Treatment With Anti–Epidermal Growth Factor Receptor Antibody Drug Conjugate MRG003 in Patients With Advanced Solid Tumors

Published:2022-07-01 Issue:7 Volume:8 Page:1042
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Qiu Miao-Zhen¹,Zhang Yang²,Guo Ye³,Guo Wei⁴,Nian Weiqi⁵,Liao Wangjun⁶,Xu Zhongyuan⁶,Zhang Wenxue⁷,Zhao Hong-Yun²,Wei Xiaoli¹,Xue Liqiong³,Tang Wenbo³,Wu Yunteng⁴,Ren Guoxin⁴,Wang Ling⁵,Xi Jingle⁶,Jin Yongshuai⁸,Li Hu⁹,Hu Chaohong⁹,Xu Rui-Hua¹¹⁰

Affiliation:

1. Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, People’s Republic of China

2. Department of Clinical Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

3. Department of Oncology, Shanghai East Hospital Tongji University School of Medicine, Shanghai, China

4. Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, China

5. Chongqing Cancer Institute, Chongqing University Cancer Hospital, Chongqing, China

6. Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China

7. Radiation Oncology Department, Tianjin Medical University General Hospital, Tianjin, Tianjin, China

8. Lepu Biopharma Co, Beijing, China

9. Shanghai Miracogen Inc, Shanghai, China

10. Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, People’s Republic of China

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2792015/jamaoncology_qiu_2022_br_220006_1658255496.01477.pdf

Reference15 articles.

1. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities.;Yarden;Eur J Cancer,2001

2. Review on epidermal growth factor receptor (EGFR) structure, signaling pathways, interactions, and recent updates of EGFR inhibitors.;Sabbah;Curr Top Med Chem,2020

3. Single-molecule imaging of EGFR signalling on the surface of living cells.;Sako;Nat Cell Biol,2000

4. Targeting the EGFR signaling pathway in cancer therapy.;Seshacharyulu;Expert Opin Ther Targets,2012

5. Silence of chromosomal amplifications in colon cancer.;Platzer;Cancer Res,2002

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of antibody‐drug conjugates in cancer: Overview and prospects;Cancer Communications;2023-12-30

2. Emerging Antibody-Drug Conjugate Therapies and Targets for Metastatic Renal Cell Carcinoma;Kidney Cancer;2023-12-29

3. The clinical development of antibody-drug conjugates for non-small cell lung cancer therapy;Frontiers in Immunology;2023-12-11

4. A narrative review of antibody–drug conjugates in EGFR-mutated non-small cell lung cancer;Frontiers in Oncology;2023-12-01

5. Advances of radiotherapy combined with targeted therapy for nasopharyngeal carcinoma;Radiation Medicine and Protection;2023-12